Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.37 |
| ▸ | FASN | P49327 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13645840 | 0.86 | ALDH1A1 (0.47) | MMEBTKEPHX2PDE7AFASN | |
| SCHEMBL23826244 | 0.83 | BTK (0.43) | MMEBTKEPHX2FASNTSHR | |
| SCHEMBL16444188 | 0.83 | BTK (0.43) | MMEBTKEPHX2FASNTSHR | |
| SCHEMBL16325112 | 0.83 | BTK (0.43) | MMEBTKEPHX2FASNTSHR | |
| SCHEMBL15404590 | 0.83 | MME (0.35) | MMEPDE7AFASNTSHRGRIN1 | |
| SCHEMBL15404591 | 0.83 | MME (0.35) | MMEPDE7AFASNTSHRGRIN1 | |
| SCHEMBL23826543 | 0.79 | BTK (0.47) | BTKEPHX2TSHRGRIN1GRIN2B | |
| SCHEMBL23826924 | 0.79 | BTK (0.47) | BTKEPHX2TSHRGRIN1GRIN2B | |
| SCHEMBL14658519 | 0.79 | MME (0.46) | MMEBTKEPHX2PDE7AFASN | |
| SCHEMBL3715481 | 0.79 | MME (0.46) | MMEBTKEPHX2PDE7AFASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER, INC. | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | ENGASE, ENPEP, CPN1 | MME 7/4885BTK 3917/4885EPHX2 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.